FT : EU states resist Brussels over €66bn budget top-up

EU states resist Brussels over €66bn budget top-up
European Commission says more funding needed to cover rising interest costs and Ukraine-related expenses

Brussels faces resistance from frugal European capitals as it seeks an additional €66bn for the bloc’s common budget to cover rising interest costs, migration-related expenses and commitments stemming from the war in Ukraine. 

As part of an overhaul of the EU’s seven-year budget proposed on Tuesday, the European Commission seeks support for a €50bn package for Ukraine until 2027, of which a third would be grants and the remainder loans, as well as cash reoriented from other areas of the budget.
The commission also plans to set up a dedicated mechanism to handle interest cost overruns, with an indicative value of just under €19bn over the four-year period.

Ursula von der Leyen, the commission president, called the extra cash request a “very targeted and limited proposal” that aims to respond to a world that has radically changed since the inception of the EU’s latest seven-year budget in 2021.

But countries including Germany and the Netherlands have made it clear that while they are supportive of extra funding for Kyiv, they expect the commission to take a disciplined approach to its budget at a time when national finances are also under pressure. 

Christian Lindner, the German finance minister, warned on Friday that EU capitals were facing “very difficult budget negotiations” at home, and so “this is not the time to ask member states for more funding”. He added, however, that the attitude towards support for Ukraine was different. 

Any demands for fresh cash in areas other than Ukraine will be a “very tough sell”, said one northern EU diplomat on Tuesday as the commission prepared to unveil its budget proposals. On Monday, France’s finance minister Bruno Le Maire said Paris would save “at least €10bn” to rebalance French public spending by 2027. 

The interest repayments instrument would be designed to handle rising costs stemming from the common borrowing under the €800bn Covid-19 recovery programme agreed by member states in 2020. Those costs have spiralled as central banks have raised interest rates in response to record eurozone inflation, with the budget commissioner Johannes Hahn telling MEPs earlier in June that debt-related costs are set to double in 2024 alone from €2.1bn to €4bn.

But any proposals to ask for fresh funds from member states to deal with the rising debt costs will face tough questions from frugal member states, as they urge the commission to find savings elsewhere. 

“We didn’t see the extent of interest rate increases coming,” acknowledged one EU diplomat. “We have an interest in being the most credible possible and showing that we are a reliable debt issuer.”

The commission also unveiled plans to create new so-called own resources — mostly stemming from bloc-wide taxes and levies — which could be used to repay recovery fund debts in the coming decades. They include a new levy linked to member states’ business sectors, but attaining unanimous support for these new revenue lines will be very difficult. 

Brussels made additional funding requests in other areas, including €15bn for migration and support for neighbouring countries and a €10bn plan to support investments in technology. 

A key goal of the budget review is to put financial support for Ukraine on a firmer footing. This entails the creation of a funding mechanism that would guarantee low-cost loans underpinning Ukraine’s public finances over the next four years, extending an EU programme worth €18bn this year. 

Diplomats said the commission’s demand for fresh support for Ukraine should prove the least contentious element of the budget discussions, given the EU’s shared goal of backing Kyiv and its defence against the Russian invasion.

The €50bn package would “give visibility to the Ukrainians and send a signal to the US and UK that there is a ceiling and we’re not going to pay for everything”, one EU diplomat said.

>>> US Research Calls

Research Calls

  • Upgrades:
    • Avis Budget (CAR) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $230
    • Baidu (BIDU) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $190
    • EPR Properties (EPR) upgraded to Mkt Outperform from Mkt Perform at JMP Securities; tgt $54
    • Melco Resorts & Entertainment (MLCO) upgraded to Outperform from Neutral at Credit Suisse; tgt raised to $18.20
    • Philip Morris International (PM) upgraded to Buy from Neutral and placed on 90-day Positive Catalyst Watch at Citigroup; tgt raised to $117
    • Studio City (MSC) upgraded to Outperform from Neutral at Credit Suisse; tgt raised to $11
    • Universal Stainless/Alloy (USAP) upgraded to Overweight from Sector Weight at KeyBanc Capital Markets; tgt $16
    • US Foods (USFD) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $54
  • Downgrades:
    • Abcam (ABCM) downgraded to Sector Perform from Outperform at RBC Capital Mkts; tgt lowered to $22
    • Gates Industrial (GTES) downgraded to Neutral from Buy at Goldman; tgt $14.50
    • Milestone Pharmaceuticals (MIST) downgraded to Hold from Buy at Jefferies; tgt lowered to $4
    • Palantir Technologies (PLTR) downgraded to Outperform from Strong Buy at Raymond James; tgt raised to $18
    • Performance Food Group (PFGC) downgraded to Equal-Weight from Overweight at Morgan Stanley; tgt lowered to $66
    • Portland Gen Elec (POR) downgraded to Neutral from Buy at Guggenheim
    • Public Service (PEG) downgraded to Neutral from Buy at Seaport Research Partners
  • Others:
    • Allstate (ALL) initiated with an Equal-Weight at Morgan Stanley; tgt $117
    • Arch Capital (ACGL) initiated with an Overweight at Morgan Stanley; tgt $92
    • Amazon (AMZN) placed on US 1 List at BofA Securities
    • American Intl (AIG) initiated with an Equal-Weight at Morgan Stanley; tgt $57
    • Aon (AON) initiated with an Equal-Weight at Morgan Stanley; tgt $340
    • Atmus Filtration Technologies (ATMU) initiated with a Buy at BofA Securities; tgt $25
    • Atmus Filtration Technologies (ATMU) initiated with a Buy at Goldman; tgt $30
    • Atmus Filtration Technologies (ATMU) initiated with an Outperform at Robert W. Baird; tgt $24
    • Atmus Filtration Technologies (ATMU) initiated with an Overweight at JP Morgan; tgt $28
    • Atmus Filtration Technologies (ATMU) initiated with an Overweight at Wells Fargo; tgt $24
    • Calliditas Therapeutics AB (CALT) initiated with a Buy at H.C. Wainwright; tgt $60
    • Centene (CNC) initiated with a Neutral at UBS; tgt $72
    • Chubb (CB) initiated with an Equal-Weight at Morgan Stanley; tgt $192
    • Confluent (CFLT) initiated with a Peer Perform at Wolfe Research
    • Delta Air Lines (DAL) placed on 30-day Positive Catalyst Watch at Citigroup
    • Element Solutions (ESI) initiated with an Outperform at BMO Capital Markets; tgt $23
    • Enhabit Inc. (EHAB) initiated with an Underperform at SVB Securities; tgt $10
    • Entegris (ENTG) initiated with an Outperform at BMO Capital Markets; tgt $129
    • Everest Re (RE) initiated with an Overweight at Morgan Stanley; tgt $429
    • GitLab (GTLB) initiated with a Peer Perform at Wolfe Research
    • Hartford Financial (HIG) initiated with an Equal-Weight at Morgan Stanley; tgt $71
    • Lemonade (LMND) initiated with an Underweight at Morgan Stanley; tgt $14
    • Manpower (MAN) initiated with a Buy at Redburn; tgt $94
    • Marsh McLennan (MMC) initiated with an Equal-Weight at Morgan Stanley; tgt $202
    • Molina Healthcare (MOH) initiated with a Neutral at UBS; tgt $310
    • Progressive (PGR) initiated with an Equal-Weight at Morgan Stanley; tgt $135
    • RenaissanceRe (RNR) initiated with an Equal-Weight at Morgan Stanley; tgt $222
    • Robert Half (RHI) initiated with a Neutral at Redburn; tgt $76
    • Travelers (TRV) initiated with an Equal-Weight at Morgan Stanley; tgt $185
    • Willis Towers Watson (WTW) initiated with an Equal-Weight at Morgan Stanley; tgt $251

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:

  • X -0.8% (guidance)

Other news:

  • ACLX -12.6% (announces clinical hold for its iMMagine-1 Phase 2 Clinical Program)
  • PHVS -5% (entered into a subscription agreement relating to the offer and sale of an aggregate of 6,951,340 ordinary shares of the Company)
  • RYTM -3% (Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023)
  • DDD -2.6% (updates its shareholders on its proposal for Stratasys (SSYS))
  • BABA -2.4% (announces Chairman and CEO succession plan)
  • BEEM -2.4% (acquires Amiga; provides guidance; prices 2.5 mln shares of common stock at $9.00 per share)
  • ATI -2% (secures estimated $1.2 billion in aerospace and defense sales commitments)
  • FUSN -1.3% (files for 4,784,689 share common stock offering by selling shareholders)

Analyst comments:

  • PFGC -1.1% (downgraded to Equal-Weight from Overweight at Morgan Stanley)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:

  • AVNS +4.7% (guidance), RTX +0.6% (guidance)

Other news:

  • DICE +38.4% (Lilly (LLY) to acquire DICE Therapeutics to advance innovation in immunology for $48 per share in cash)
  • VERA +8.8% (Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress)
  • PGEN +6.6% (Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis)
  • ENTA +5% (announces positive data from a phase 1 clinical study of EDP-323, an oral, l-protein inhibitor in development for the treatment of respiratory syncytial virus)
  • MIST +3.7% (announces the publication of results in The Lancet from the Phase 3 RAPID clinical trial evaluating etripamil nasal spray, the Company's investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia)
  • NR +3.3% (exploring strategic alternatives for the long-term positioning of its Fluids Systems division)
  • SNY +3.1% (prevails in Zantac arbitration initiated by Boehringer Ingelheim)
  • RDNT +2.8% (announces closing of public offering of 8.71 mln shares of common stock at price of $29.75/share, which includes entire overallotment option to underwriters of 1.14 mln shares)
  • CPRX +2.4% (to license North American rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals)
  • PYPL +1.8% (PayPal and KKR (KKR) announce an exclusive multi-year agreement for a €3 billion replenishing loan commitment)
  • NKLA +1.7% (announces update on business optimization efforts, including streamlining of operations and decrease in cash spend; to reduce headcount, resulting in decrease in personnel-related cash spend by more than $50 mln annually)
  • BF.B +1.7% (divests Finlandia Vodka for $220 mln)
  • KEN +1.6% (announces the commencement by OPC's subsidiary CPV Group of construction of a solar power project with a capacity of 170 MW in Maryland, United States, in the PJM market, also called the Backbone project)
  • IOVA +1.4% (files mixed securities shelf offering)
  • KDNY +1.4% (Presents Data from CHK-336 Phase 1 Trial)
  • BBIO +1% (presents updated six month results from its phase 2 cohort 5 trial of infigratinib in Achondroplasia at the Endocrine Society 2023 Annual Conference)

Analyst comments:

  • CAR +4.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
  • MLCO +2.2% (upgraded to Outperform from Neutral at Credit Suisse)
  • BIDU +0.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)

>>> US Early premarket gappers

Early premarket gappers

  • Gapping up:
    • DICE +40.2%, VERA +8.8%, FUSN +4.9%, RDNT +3.9%, NKLA +3.4%, SNY +2.7%, MCRB +2.4%, NMG +2.4%, CPRX +2.2%, KEN +1.6%, KDNY +1.4%, EVER +1.1%, EXK +1%
  • Gapping down:
    • ACLX -18.9%, BEEM -7.4%, RYTM -3%, BABA -2.4%, HEAR -2%, X -1.3%, DAL -0.7%, BF.B -0.5%

>>> Weekend Reading Summary

Weekend Reading Summary

Macro Related:
  • Chinese banks lowered lending rates (FXI). WSJ
  • Secretary of State Antony Blinken met with Chinese President Xi to ensure that competitive relationship does not veer into a conflict. Mr. Xi praised both sides for making progress (FXI). NY Times
  • China and Cuba are negotiating terms for joint military training facility in Cuba. WSJ
  • Homeless numbers rising in several American cities. WSJ

Stock Specific:

  • Positive views on UMG & WMG. Barron's
  • Positive view on Adidas (ADDYY). Barron's
  • Positive view on Oracle (ORCL). Barron's
  • Positive view on KR, LEN, AMD. Barron's
  • Stellantis (STLA) limits gasoline powered car sales in 14 states amid emission rules. Bloomberg
  • Regulators are concerned about commercial real estate amid increasing vacancies (ESRT, VNO, SLG, BXP, ARE, CUZ, BDN, PDM). Bloomberg
  • Alibaba (BABA) co founder Jack Ma made appearance at company event. Bloomberg
  • GE Aerospace (GE) CEO Larry Culp says all options on table regarding A220 engine (EADSY). Reuters
  • Tesla (TSLA) offers discounts on Model S and Model X. ElecTrek
  • Google (GOOG) wants to move some Pixel production to India. Bloomberg
  • AstraZeneca (AZN) planning to spin off China unit. FT
  • Silicon Valley Bank (SIVB) customers in Asia might be on hook for loans. WSJ
  • Adobe (ADBE) acquisition of Figma could face long EU investigation. FT
  • UBS (UBS) will face hundreds of millions of dollars in penalties over Archegos Capital. FT
  • Abu Dhabi's sovereign wealth fund in discussions to take Lazard (LAZ) private. FT

FT : Northvolt receives $400mn funding from Canadian pension fund

Northvolt receives $400mn funding from Canadian pension fund
Investment Management Corporation of Ontario to boost Swedish battery start-up’s international expansion

One of Canada’s largest pension groups has invested $400mn into Northvolt, as the Swedish battery start-up pushes ahead with plans to build an additional factory in Germany. 

The Investment Management Corporation of Ontario — which has about $73bn invested and pools pensions from the region’s public sector — has bought convertible loan notes in the battery group, it said on Tuesday.

Northvolt, founded in 2017, is Europe’s largest homegrown battery maker, and its expansion is core to the region’s aim to avoid ceding battery leadership to Asian rivals, particularly China. 

The group has been constantly seeking funding as it expands from its current site near the Arctic Circle and is considering a stock market listing next year. 

“We’re excited to partner with IMCO’s fundamental equities and global infrastructure teams to build the future of clean energy together,” said Alexander Hartman, chief financial officer of Northvolt. “This investment fuels our expansion efforts, allowing us to further extend our global footprint and drive sustainable progress in our mission to deliver the world’s greenest battery.”

Convertible notes are debt that can convert to equity if certain conditions are met, and are an increasingly popular route for private groups to make large investments.
The deal is IMCO’s largest in Europe to date.

For Northvolt, the latest funding round is one of several it expects to make as it targets global expansion. It is in talks to raise about $5bn in equity financing, the FT reported in March, with a deal anticipated later this year.

This comes on top of the $1.1bn it raised through convertible notes last July, taking the total amount of debt and equity financing it has raised since its founding to $8bn. 

But the business is also examining a larger stock market listing, one that could give it a valuation of $20bn. The company is in talks with several banks about the move, with any float unlikely to happen until at least next year. 

The company is already Europe’s largest homegrown battery manufacturer, with aims to build a second facility in Sweden’s Gothenburg alongside Volvo.

Last month, the group picked Germany over the US for its third plant, after Berlin agreed to significant subsidies to counter the Inflation Reduction Act from the US.